Chemotactic Activity of S100A7 (Psoriasin) Is Mediated by the Receptor for Advanced Glycation End Products and Potentiates Inflammation with Highly Homologous but Functionally Distinct S100A15

Ronald Wolf; O. M. Zack Howard; Hui-Fang Dong; Christopher Voscopoulos; Karen Boeshans; Jason Winston; Rao Divi; Michele Gunsior; Paul Goldsmith; Bijan Ahvazi; Triantafyllos Chavakis; Joost J. Oppenheim; Stuart H. Yuspa

doi:10.4049/JIMMUNOL.181.2.1499

Chemotactic Activity of S100A7 (Psoriasin) Is Mediated by the Receptor for Advanced Glycation End Products and Potentiates Inflammation with Highly Homologous but Functionally Distinct S100A15

Ronald Wolf
, O. M. Zack Howard
, Hui-Fang Dong
, Christopher Voscopoulos
, Karen Boeshans
, Jason Winston
, Rao Divi
, Michele Gunsior
, Paul Goldsmith
, Bijan Ahvazi
, Triantafyllos Chavakis
, Joost J. Oppenheim
, Stuart H. Yuspa

*Laboratory of Cancer Biology and Genetics,
§Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, Center for Cancer Research, and
Science Applications International Corporation
National Institutes of Health
‡Antibody and Protein Purification Unit, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892;
†Experimental Immunology Branch, and

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Immunology
Volume	181
Issue number	2
DOIs	https://doi.org/10.4049/JIMMUNOL.181.2.1499
State	Published - Jul 15 2008
Externally published	Yes

Disciplines

Cell Biology
Biology

Access to Document

10.4049/JIMMUNOL.181.2.1499License: Unspecified

Cite this

Wolf, R., Howard, O. M. Z., Dong, H.-F., Voscopoulos, C., Boeshans, K., Winston, J., Divi, R., Gunsior, M., Goldsmith, P., Ahvazi, B., Chavakis, T., Oppenheim, J. J., & Yuspa, S. H. (2008). Chemotactic Activity of S100A7 (Psoriasin) Is Mediated by the Receptor for Advanced Glycation End Products and Potentiates Inflammation with Highly Homologous but Functionally Distinct S100A15. Journal of Immunology, 181(2). https://doi.org/10.4049/JIMMUNOL.181.2.1499

Chemotactic Activity of S100A7 (Psoriasin) Is Mediated by the Receptor for Advanced Glycation End Products and Potentiates Inflammation with Highly Homologous but Functionally Distinct S100A15. / Wolf, Ronald; Howard, O. M. Zack; Dong, Hui-Fang et al.
In: Journal of Immunology, Vol. 181, No. 2, 15.07.2008.

Research output: Contribution to journal › Article › peer-review

Wolf, R, Howard, OMZ, Dong, H-F, Voscopoulos, C, Boeshans, K, Winston, J, Divi, R, Gunsior, M, Goldsmith, P, Ahvazi, B, Chavakis, T, Oppenheim, JJ & Yuspa, SH 2008, 'Chemotactic Activity of S100A7 (Psoriasin) Is Mediated by the Receptor for Advanced Glycation End Products and Potentiates Inflammation with Highly Homologous but Functionally Distinct S100A15', Journal of Immunology, vol. 181, no. 2. https://doi.org/10.4049/JIMMUNOL.181.2.1499

@article{7326b96fd81b495ea59b037a6236fa55,

title = "Chemotactic Activity of S100A7 (Psoriasin) Is Mediated by the Receptor for Advanced Glycation End Products and Potentiates Inflammation with Highly Homologous but Functionally Distinct S100A15",

author = "Ronald Wolf and Howard, \{O. M. Zack\} and Hui-Fang Dong and Christopher Voscopoulos and Karen Boeshans and Jason Winston and Rao Divi and Michele Gunsior and Paul Goldsmith and Bijan Ahvazi and Triantafyllos Chavakis and Oppenheim, \{Joost J.\} and Yuspa, \{Stuart H.\}",

note = "Human S100A7 (hS100A7, psoriasin) was first identified as a protein upregulated in inflamed hyperplastic psoriatic skin 1. Since then, human S100A7 (hS100A7) has been widely studied because it is differentially expressed and released during inflammation 2-5. Recently, hS100A15, highly homologous to hS100A7, was also identified as upregulated in psoriasis, thereby suggesting a role in the inflammatory phenotype 6.",

year = "2008",

month = jul,

day = "15",

doi = "10.4049/JIMMUNOL.181.2.1499",

language = "American English",

volume = "181",

journal = "Journal of Immunology",

number = "2",

}

TY - JOUR

T1 - Chemotactic Activity of S100A7 (Psoriasin) Is Mediated by the Receptor for Advanced Glycation End Products and Potentiates Inflammation with Highly Homologous but Functionally Distinct S100A15

AU - Wolf, Ronald

AU - Howard, O. M. Zack

AU - Dong, Hui-Fang

AU - Voscopoulos, Christopher

AU - Boeshans, Karen

AU - Winston, Jason

AU - Divi, Rao

AU - Gunsior, Michele

AU - Goldsmith, Paul

AU - Ahvazi, Bijan

AU - Chavakis, Triantafyllos

AU - Oppenheim, Joost J.

AU - Yuspa, Stuart H.

N1 - Human S100A7 (hS100A7, psoriasin) was first identified as a protein upregulated in inflamed hyperplastic psoriatic skin 1. Since then, human S100A7 (hS100A7) has been widely studied because it is differentially expressed and released during inflammation 2-5. Recently, hS100A15, highly homologous to hS100A7, was also identified as upregulated in psoriasis, thereby suggesting a role in the inflammatory phenotype 6.

PY - 2008/7/15

Y1 - 2008/7/15

UR - https://www.europepmc.org/articles/PMC2435511/

U2 - 10.4049/JIMMUNOL.181.2.1499

DO - 10.4049/JIMMUNOL.181.2.1499

M3 - Article

VL - 181

JO - Journal of Immunology

JF - Journal of Immunology

IS - 2

ER -

Chemotactic Activity of S100A7 (Psoriasin) Is Mediated by the Receptor for Advanced Glycation End Products and Potentiates Inflammation with Highly Homologous but Functionally Distinct S100A15

Disciplines

Access to Document

Other files and links

Cite this